Trial · NCT07891650
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in Montreal Cognitive Assessment (MoCA) Total Score at Week 24 | Baseline and week 24 (end of treatment) | The Montreal Cognitive Assessment (MoCA) assesses global cognitive function. Total scores range from 0 to 30, with higher scores indicating better cognitive function. Change will be calculated as the week 24 total score minus the baseline total score. A positive change indicates improvement. |
| Secondary | Change From Baseline in Montreal Cognitive Assessment (MoCA) Total Score at Three Months After Treatment | Baseline and three months after completion of the 24-week treatment period | The Montreal Cognitive Assessment (MoCA) assesses global cognitive function. Total scores range from 0 to 30, with higher scores indicating better cognitive function. Change will be calculated as the three-month post-treatment follow-up total score minus the baseline total score. A positive change indicates improvement. |
| Secondary | Change From Baseline in Mini-Mental State Examination (MMSE) Total Score | Baseline, week 24 (end of treatment), and three months after completion of treatment | The Mini-Mental State Examination (MMSE) assesses global cognitive function. Total scores range from 0 to 30, with higher scores indicating better cognitive function. Changes will be calculated separately as the total score at each post-baseline assessment minus the baseline total score. Positive changes indicate improvement. |
| Secondary | Change From Baseline in Clinical Dementia Rating (CDR) Global Score | Baseline, week 24 (end of treatment), and three months after completion of treatment | The Clinical Dementia Rating (CDR) global score assesses the severity of cognitive and functional impairment. Possible scores are 0, 0.5, 1, 2, and 3, with higher scores indicating greater impairment. Changes will be calculated separately as the global score at each post-baseline assessment minus the baseline global score. Negative changes indicate improvement. |
| Secondary | Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score | Baseline, week 24 (end of treatment), and three months after completion of treatment | The Clinical Dementia Rating-Sum of Boxes (CDR-SB) is calculated by summing ratings across six cognitive and functional domains. Scores range from 0 to 18, with higher scores indicating greater impairment. Changes will be calculated separately as the score at each post-baseline assessment minus the baseline score. Negative changes indicate improvement. |
| Secondary | Change From Baseline in Activities of Daily Living (ADL) Score | Baseline, week 24 (end of treatment), and three months after completion of treatment | Activities of daily living will be assessed using the ADL scale. Changes will be calculated separately as the score at each post-baseline assessment minus the baseline score. |
| Secondary | Change From Baseline in Auditory Verbal Learning Test (AVLT) Scores | Baseline, week 24 (end of treatment), and three months after completion of treatment | Verbal learning and memory will be assessed using the Auditory Verbal Learning Test (AVLT). Changes will be calculated separately as each prespecified AVLT score at each post-baseline assessment minus its corresponding baseline score. |
| Secondary | Change From Baseline in Trail Making Test (TMT) Performance | Baseline, week 24 (end of treatment), and three months after completion of treatment | Performance on the Trail Making Test (TMT) will be assessed. Changes will be calculated separately as the prespecified performance measure at each post-baseline assessment minus its corresponding baseline measure. |
| Secondary | Change From Baseline in Digit Span Test (DST) Scores | Baseline, week 24 (end of treatment), and three months after completion of treatment | Attention and working memory will be assessed using the Digit Span Test (DST). Changes will be calculated separately as each prespecified score at each post-baseline assessment minus its corresponding baseline score. |
| Secondary | Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score | Baseline, week 24 (end of treatment), and three months after completion of treatment | Neuropsychiatric symptoms will be assessed using the Neuropsychiatric Inventory (NPI). Changes will be calculated separately as the total score at each post-baseline assessment minus the baseline total score. Higher scores indicate more severe neuropsychiatric symptoms; negative changes indicate improvement. |
| Other | Change From Baseline in Resting-State and Task-Related Electroencephalographic Measures | Baseline, week 1 (end of induction), week 24 (end of treatment), and three months after completion of treatment | Changes in resting-state and task-related electroencephalographic measures will be assessed, including spectral power, functional connectivity, and cognitive event-related potentials. Each prespecified measure will be compared with its corresponding baseline value. |
| Other | Change From Baseline in Multimodal Magnetic Resonance Imaging Measures | Baseline, week 24 (end of treatment), and three months after completion of treatment | Changes in multimodal magnetic resonance imaging measures will be assessed to characterize brain network function and white matter microstructure. Each prespecified measure will be compared with its corresponding baseline value. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07891650/registered